A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Clinical trial NCT05963074 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05963074
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-30
- Primary completion
- 2027-12-15
- Enrollment
- 333
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.